{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:08:29Z","timestamp":1790712509738,"version":"4.1.0"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900182"],"award-info":[{"award-number":["81900182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Invasive fungal diseases (IFD) are a major global public health concern. The incidence of IFD has increased the demand for antifungal agents. Isavuconazole (ISA) is a new triazole antifungal agent that has shown promising efficacy in the prophylaxis and treatment of invasive fungal diseases. The aim of this review is to summarize the recent real-world experiences of using ISA for the treatment and prevention of IFD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a comprehensive literature search of the MEDLINE, PubMed, Embase, and Cochrane databases for clinical applications of ISA in the real world. Tables and reference lists are presented for this systematic review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>IFD poses a major threat to public health and causes high mortality rates. ISA may provide a good treatment. For example, the efficacy of ISA in the treatment of invasive aspergillosis (IA) is comparable to that of voriconazole, and its efficacy in the treatment of invasive mucormycosis (IM) is similar to that of liposomal amphotericin B (L-AmB); therefore, ISA is recommended as the first-line treatment for IA and IM. ISA can also achieve good efficacy in the treatment of invasive candidiasis (IC) and can be used as an alternative to de-escalation therapy after first-line drug therapy. In addition, most studies have shown the efficacy and safety of ISA for the prophylaxis of IFD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Taken together, ISA are expected to become a new choice for the treatment and prevention of IFD because of their good tolerability, high bioavailability, and few drug interactions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2022.1049959","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T04:41:26Z","timestamp":1669869686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical research advances of isavuconazole in the treatment of invasive fungal diseases"],"prefix":"10.3389","volume":"12","author":[{"given":"Tingting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29807","article-title":"Successful isavuconazole salvage therapy for cerebral mucormycosis in a child with relapsed leukemia: A light in the dark tunnel","author":"Alali","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2217\/fmb.15.34","article-title":"Isavuconazole: a new extended spectrum triazole for invasive mold diseases","volume":"10","author":"Ananda-Rajah","year":"2015","journal-title":"Future Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0029021","DOI":"10.1128\/AAC.00290-21","article-title":"Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients","volume":"65","author":"Arrieta","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/INF.0000000000002671","article-title":"Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients","volume":"39","author":"Ashkenazi-Hoffnung","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e13313","DOI":"10.1111\/tid.13313","article-title":"Successful treatment of aspergillus fumigatus sternal osteomyelitis with isavuconazole in a heart transplant recipient","volume":"22","author":"Assaf","year":"2020","journal-title":"Transpl. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2217\/fmb-2016-0231","article-title":"The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK","volume":"12","author":"Bagshaw","year":"2017","journal-title":"Future Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1237125","DOI":"10.1155\/2022\/1237125","article-title":"Clinical manifestations of pulmonary mucormycosis in recipients of allogeneic hematopoietic stem cell transplantation: A 21-case series report and literature review","volume":"2022","author":"Bao","year":"2022","journal-title":"Can. Respir. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1093\/mmy\/myy070","article-title":"Chronic pulmonary aspergillosis update: A year in review","volume":"57","author":"Barac","year":"2019","journal-title":"Med. Mycol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e27281","DOI":"10.1002\/pbc.27281","article-title":"Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients","volume":"65","author":"Barg","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/mmy\/myab025","article-title":"Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"59","author":"Bogler","year":"2021","journal-title":"Med. Mycol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/myc.12885","article-title":"Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events","volume":"62","author":"Bongomin","year":"2019","journal-title":"Mycoses"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: An open-label, prospective, phase 2 study","volume":"72","author":"Bose","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/myc.12924","article-title":"Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre","volume":"62","author":"Bowen","year":"2019","journal-title":"Mycoses"},{"key":"B14","doi-asserted-by":"publisher","first-page":"101007","DOI":"10.1016\/j.mycmed.2020.101007","article-title":"Mucormycosis treatment: Recommendations, latest advances, and perspectives","volume":"30","author":"Brunet","year":"2020","journal-title":"J. Mycol. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e320","DOI":"10.1097\/01.HS9.0000563348.29099.4a","article-title":"Isavuconazole in hematological patients: Results of a real-life multicentre observational seifem study","volume":"3","author":"Cattaneo","year":"2019","journal-title":"Hemasphere"},{"key":"B16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin b-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole","volume":"80","author":"Chen","year":"2020","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/myc.12778","article-title":"Isavuconazole for treatment of rare invasive fungal diseases","volume":"61","author":"Cornely","year":"2018","journal-title":"Mycoses"},{"key":"B20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40360-018-0273-7","article-title":"Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole","volume":"19","author":"Cornu","year":"2018","journal-title":"A Case Rep. BMC Pharmacol. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jof8010074","article-title":"Real-world use of isavuconazole as primary therapy for invasive fungal infections in high-risk patients with hematologic malignancy or stem cell transplant","volume":"8","author":"Dagher","year":"2022","journal-title":"J. Fungi (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1128\/JCM.01190-13","article-title":"Isavuconazole activity against aspergillus lentulus, neosartorya udagawae, and cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility","volume":"51","author":"Datta","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01783-19","article-title":"A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation","volume":"64","author":"Decembrino","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1097\/MPH.0000000000001508","article-title":"Isavuconazole treatment of cerebral and pulmonary aspergillosis in a pediatric patient with acute lymphoblastic leukemia: Case report and review of literature","volume":"42","author":"De Leonardis","year":"2020","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur. Respir. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/jac\/dkac035","article-title":"Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules","volume":"77","author":"Dieringer","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/myc.12851","article-title":"Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients","volume":"62","author":"DiPippo","year":"2019","journal-title":"Mycoses"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040324","article-title":"Isavuconazole: Mechanism of action, clinical efficacy, and resistance","volume":"6","author":"Ellsworth","year":"2020","journal-title":"J. Fungi (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12879-019-3683-2","article-title":"Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden","volume":"19","author":"Floros","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0040-1701215","article-title":"Invasive candidiasis","volume":"41","author":"Gonzalez-Lara","year":"2020","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1093\/cid\/ciz076","article-title":"Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin b","volume":"68","author":"Groll","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"742","DOI":"10.2214\/AJR.17.18792","article-title":"Pulmonary mucormycosis: Radiologic features at presentation and over time","volume":"210","author":"Hammer","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12325-016-0443-1","article-title":"Cost-effectiveness analysis of isavuconazole vs. voriconazole as first-line treatment for invasive aspergillosis","volume":"34","author":"Harrington","year":"2017","journal-title":"Adv. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/myc.12910","article-title":"Real-world use-isavuconazole at a large academic medical center","volume":"62","author":"Hassouna","year":"2019","journal-title":"Mycoses"},{"key":"B37","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3111\/13696998.2016.1164175","article-title":"Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial","volume":"19","author":"Horn","year":"2016","journal-title":"J. Med. Econ."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/myc.13336","article-title":"Reimbursement of innovative pharmaceuticals in English and Spanish hospitals-the example of isavuconazole","volume":"64","author":"Jeck","year":"2021","journal-title":"Mycoses"},{"key":"B39","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1093\/mmy\/myy052","article-title":"Broad spectrum triazoles for invasive mould infections in adults: Which drug and when","volume":"57","author":"Jenks","year":"2019","journal-title":"Med. Mycol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13613-021-00818-4","article-title":"Poor outcome associated with mucormycosis in critically ill hematological patients: results of a multicenter study","volume":"11","author":"Jestin","year":"2021","journal-title":"Ann. Intensive Care"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/FTD.0000000000000952","article-title":"Antifungal drugs TDM: Trends and update","volume":"44","author":"Kably","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"B43","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT interval shortening with isavuconazole: In vitro and In vivo effects on cardiac repolarization","volume":"101","author":"Keirns","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1093\/ofid\/ofu051.99","article-title":"A phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole versus voriconazole in patients with invasive mold disease (SECURE): Outcomes in invasive aspergillosis patients","volume":"1","author":"Kontoyiannis","year":"2014","journal-title":"Open Forum Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: The ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mycmed.2018.02.002","article-title":"Isavuconazole: A new broad-spectrum azole. part 2: pharmacokinetics and clinical activity","volume":"28","author":"Ledoux","year":"2018","journal-title":"J. Mycol. Med."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00349","article-title":"Efficacy of posaconazole prophylaxis for fungal disease in hematology patients treated with chemotherapy and transplantation: An open-label, prospective, observational study","volume":"11","author":"Li","year":"2020","journal-title":"Front. Microbiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1055\/s-0035-1562903","article-title":"Voriconazole: How to use this antifungal agent and what to expect","volume":"36","author":"Malani","year":"2015","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"W137","DOI":"10.2214\/AJR.18.19784","article-title":"The importance of the reversed halo sign in the diagnosis of pulmonary mucormycosis","volume":"211","author":"Marchiori","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s40262-018-0673-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of isavuconazole","volume":"57","author":"McCarthy","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1093\/jac\/dkaa274","article-title":"Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube","volume":"75","author":"McCreary","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/myc.12731","article-title":"Isavuconazole shortens the QTc interval","volume":"61","author":"Mellinghoff","year":"2018","journal-title":"Mycoses"},{"key":"B56","doi-asserted-by":"publisher","first-page":"ofaa646","DOI":"10.1093\/ofid\/ofaa646","article-title":"Mucormycosis in hematopoietic cell transplant recipients and in patients with hematological malignancies in the era of new antifungal agents","volume":"8","author":"Miller","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e0178421","DOI":"10.1128\/spectrum.01784-21","article-title":"Safety and effectiveness of isavuconazole treatment for fungal infections in solid organ transplant recipients (ISASOT study)","volume":"10","author":"Monforte","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/myc.12862","article-title":"Invasive mucormycosis in children with cancer: A retrospective study from the infection working group of Italian pediatric hematology oncology association","volume":"62","author":"Muggeo","year":"2019","journal-title":"Mycoses"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1097\/INF.0000000000003017","article-title":"Isavuconazole as salvage therapy for refractory pediatric coccidioidal meningitis","volume":"40","author":"Naeem","year":"2021","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/jof8040362","article-title":"Experience of isavuconazole as a salvage therapy in chronic pulmonary fungal disease","volume":"8","author":"Nwankwo","year":"2022","journal-title":"J. Fungi (Basel)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11046-021-00599-1","article-title":"Isavuconazole and liposomal amphotericin b as successful combination therapy of refractory invasive candidiasis in a liver transplant recipient: A case report and literature review","volume":"187","author":"Odysseos","year":"2022","journal-title":"Mycopathologia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1177\/1078155218786028","article-title":"Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies","volume":"25","author":"Perreault","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e2020026","DOI":"10.4084\/mjhid.2020.026","article-title":"Isavuconazole therapy of disseminated and encephalic saprochaete capitata infection in an acute myeloid leukemia patient treated with midostaurin","volume":"12","author":"Perrone","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1177\/1060028015581679","article-title":"Isavuconazole: A new option for the management of invasive fungal infections","volume":"49","author":"Pettit","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11046-018-0287-0","article-title":"Isavuconazole in a successful combination treatment of disseminated mucormycosis in a child with acute lymphoblastic leukaemia and generalized haemochromatosis: A case report and review of the literature","volume":"184","author":"Pomorska","year":"2019","journal-title":"Mycopathologia"},{"key":"B66","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/s-0039-3401992","article-title":"Mucormycosis","volume":"41","author":"Reid","year":"2020","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa502","article-title":"Invasive candidiasis species distribution and trends, united states, 2009-2017","volume":"223","author":"Ricotta","year":"2020","journal-title":"J. Infect. Dis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40121-020-00315-4","article-title":"Pulmonary aspergillosis: An evolving challenge for diagnosis and treatment","volume":"9","author":"Russo","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/phar.1652","article-title":"Isavuconazole: Pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent","volume":"35","author":"Rybak","year":"2015","journal-title":"Pharmacotherapy"},{"key":"B70","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/cid\/ciaa652","article-title":"Isavuconazole is as effective as and better tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients","volume":"73","author":"Samanta","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Schmitt-Hoffmann","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01292-17","article-title":"Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats","volume":"61","author":"Schmitt-Hoffmann","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/mmy\/myz103","article-title":"Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system","volume":"58","author":"Schwartz","year":"2020","journal-title":"Med. Mycol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/jac\/dkz102","article-title":"In vitro interactions between isavuconazole and tacrolimus, cyclosporin a or sirolimus against mucorales","volume":"74","author":"Schwarz","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B75","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/cpdd.1079","article-title":"Pharmacokinetics, safety, and tolerability of single and multiple doses of isavuconazonium sulfate in healthy adult Japanese subjects","volume":"11","author":"Shirae","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s40265-016-0652-6","article-title":"Isavuconazole: A review in invasive aspergillosis and mucormycosis","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040265","article-title":"Epidemiology and diagnosis of mucormycosis: An update","volume":"6","author":"Skiada","year":"2020","journal-title":"J. Fungi (Basel)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","article-title":"A single-center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplantation","volume":"26","author":"Stern","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B79","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin b (AmBisome(\u00ae)): A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"B80","doi-asserted-by":"publisher","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.bbmt.2015.03.018","article-title":"Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study","volume":"21","author":"Sun","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B82","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/myc.13412","article-title":"Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study","volume":"65","author":"Thompson","year":"2022","journal-title":"Mycoses"},{"key":"B83","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"B85","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00228-017-2213-7","article-title":"Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics","volume":"73","author":"Townsend","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/cpdd.376","article-title":"Two phase 1, open-label, mass balance studies to determine the pharmacokinetics of (14) c-labeled isavuconazonium sulfate in healthy Male volunteers","volume":"7","author":"Townsend","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B88","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/17425255.2020.1764939","article-title":"Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation","volume":"16","author":"Van Daele","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12941-019-0311-3","article-title":"Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center","volume":"18","author":"Van Matre","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1128\/AAC.04586-14","article-title":"A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis","volume":"59","author":"Viljoen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e13469","DOI":"10.1111\/tid.13469","article-title":"Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience","volume":"23","author":"Vu","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030375","article-title":"Isavuconazole treatment for invasive fungal infections in pediatric patients","volume":"15","author":"Zimmermann","year":"2022","journal-title":"Pharm. (Basel)"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1049959\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T04:41:30Z","timestamp":1669869690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1049959\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":92,"alternative-id":["10.3389\/fcimb.2022.1049959"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.1049959","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"article-number":"1049959"}}